Finding studies
Finding studies
Take this into the appointment.
Saves the questions and what to expect into your notes, next to the visit they belong to.
Mansoor Raza Mirza, MD
CONTACT
Jeanie Tang
CONTACT
Lead
Acrivon Therapeutics
With
OncoSignature Selected Cohorts (Arms 1 and 2): Participants in Arms 1 \& 2 will be allocated into two arms based on prospectively predicted sensitivity to ACR-368 using the OncoSignature® Companion Diagnostic test, as follows: Arm 1: OncoSignature Positive tumors Arm 2: OncoSignature Negative tumors (completed) OncoSignature Unselected Cohort (Arm 3 \& Arm 4): In Arm 3 and Arm 4, participants will not require a biopsy or OncoSignature result. Participants in Arm 1 and Arm 4 will receive ACR-368 as monotherapy. Participants in Arms 2 and 3 will receive ACR-368 with ULDG sensitization. Participants in all arms will be treated until disease progression, unacceptable toxicity or any criterion for stopping the study drug or withdrawal from the trial occurs. Arms 1 and 2 do not apply to sites in the European Union (EU), which will enroll subjects in Arm 3 and Arm 4.
Age
18–any
Sex
FEMALE
Healthy volunteers
Not accepted